{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-001168","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2022-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.493945+00:00","generated_at":"2026-06-27T08:21:31.523846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Biodesix reports record full-year 2021 revenue of $54.5M; core lung diagnostic testing up 49%","bullets":["Full-year 2021 total revenue $54.5M vs $45.6M in 2020; Q4 revenue $7.2M.","Core lung diagnostic testing revenue grew 49% YoY; excluding COVID-19, annual core revenue $24.3M (+41%).","Q4 core revenue (ex-COVID) $6.8M, up 22% YoY and 13% sequentially.","Cash and cash equivalents $32.7M as of Dec 31, 2021.","CEO highlights new IQLung and GeneStrat NGS tests; company may seek additional capital."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-001168","json":"https://secwatch.observer/filing/0000950170-22-001168.json","markdown":"https://secwatch.observer/filing/0000950170-22-001168.md","text":"https://secwatch.observer/filing/0000950170-22-001168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022001168/0000950170-22-001168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022001168/bdsx-20220214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T08:21:31.523846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}